Cure8 research brief
Reliable, low‑cost lab methods to measure mesalazine in tablets help ensure pharmaceutical quality and correct dosing of 5‑ASA drugs used in ulcerative colitis and IBD.
Clinicians involved in drug formulation or pharmacology, pharmaceutical quality‑control labs, analytical chemists, and researchers studying drug assays.
This chemistry paper describes a new laboratory colorimetric (spectrophotometric) method to measure mesalazine (mesalamine, a 5-ASA drug) in pharmaceutical tablets. The authors synthesized a bis‑Schiff base coupling reagent (SH1) that forms a stable azo dye with diazotized mesalazine in alkaline medium; the resulting colored product absorbs at 530 nm.
The method is presented as simple, low‑volume, aqueous, and suitable for routine quality‑control testing of tablet formulations such as Pentasa®. The report focuses on analytical chemistry and formulation testing rather than clinical effects.
It gives method performance metrics (linearity range, limit of detection, accuracy/recovery, precision) and reports successful application to commercial tablets, supporting use in pharmaceutical quality control.
If you are a patient, clinician, or researcher, this paper signals improved laboratory options for measuring mesalazine content in drugs, but it does not provide clinical guidance about dosing, safety, or treatment choices.
This is an analytical chemistry article (abstract-level summary available). It reports a lab assay for measuring mesalazine in tablets, not a clinical study or therapeutic monitoring method for patients. Do not interpret this as clinical evidence about treatment efficacy or safety.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Coexistence of ulcerative colitis and collagenous colitis is rare but can change diagnosis and management. Stool calprotectin and biopsies helped identify and monitor disease activity, and adjusting mesalazine coincided...
This trial tests whether adding the oral antibiotic nifuroxazide to standard mesalamine improves quality of life for people with mild-to-moderate ulcerative colitis. Results, if published, could suggest a new adjunctive...
